Rent Activities

^1/ Reflects enacted levels adjusted for the 0.22 percent rescission, accounting for $218,000 in the GSA Rent program and $57,000 in the Other Rent and Rent-Related program.

Historical Funding and FTE Levels
GSA Rent

Historical Funding and FTE Levels

Other Rent and Rent-Related Activities

MISSION

Rent is part of the Salaries and Expenses Appropriation and includes Rental Payments to GSA and Other Rent and Rent Related activities.  GSA Rental Payments includes charges for all of FDA’s GSA space, both government-owned and GSA-leased.  The Other Rent and Rent-Related account includes rent and rent-related charges that are not part of the GSA account, such as costs associated with moving staff and equipment during the consolidation of FDA laboratory facilities.

REQUESTED INCREASES

Rental Payments to GSA  +$380,000

Prescription Drug User Fees +$380,000

• For FY 2002, FDA is requesting an additional $380,000.  This will bring the total to $6,240,000 in user fees to defray expected increases in costs for GSA space used in support of the user fee portion of the process for the review of human drug applications.

Other Rent and Rent Related Activities  +$6,000,000

Construction of the Center for Drug Evaluation and Research (CDER) laboratory portion of the FDA Consolidated Headquarters facility at White Oak is scheduled to be completed in FY 2002.   GSA is responsible for funding construction of the project, but FDA must fund the actual move of staff and equipment, as well as certain telecommunications and equipment costs.  FDA proposes to occupy its White Oak facility over a period of several years, and, thus, will require additional future year funding to support the phased-in relocation strategy.

• FDA is requesting an increase of $6,000,000 for facility-related costs not covered by GSA, bringing the total to $31,798,000.  FDA requests funds for one-time costs to equip and occupy the CDER laboratory portion of the facility located at White Oak. The FY 2002 funds will support telecommunications equipment and necessary connections, and moving costs. The funds will relocate the CDER laboratory functions to a new state-of-the-art facility scheduled to open in 2002, and begin the consolidation of most FDA Headquarters activities in one location, resulting in more effective and efficient operations.

JUSTIFICATION OF BASE

Rental Payments to GSA

• FDA occupies over 4.1 million net square feet of GSA space, including parking, which is under the Agency's Salaries and Expenses appropriation. By FY 2002, FDA will occupy over 4.3 million net square feet of GSA space, including parking.   As a result of negotiations between FDA and GSA to reduce rent at certain locations, increased resources are not required in FY 2001 to fund the increase in space planned.
• The GSA rent charges are billed directly to the Agency and indirectly to FDA through other agencies, and include the charges for all of FDA's GSA space, both government owned and GSA leased.  About 47 percent of the GSA rent charges are for government-owned or GSA-leased space in the Washington, D.C. area.  The largest individual rent charges are for the Parklawn Building complex, Module II in Beltsville, CFSAN's new College Park location, and the Regional offices and laboratory in Jamaica, NY.  The balance of the charges are for the Agency's field Regional Offices, District Office/Laboratory complexes, and over 130 leased offices which serve as resident posts for strategically placed field investigators.

Other Rent and Rent-Related Activities

• The Commercial Rent and Related Services account consists of recurring activities that FDA pays directly to non-Federal sources under the delegation of direct lease and service authority. (Note: This also includes recurring services for FDA-owned facilities.)  Services include rental of space, and all recurring services for building operations; i.e., utilities; and services such as janitorial, guard, grounds maintenance; and operation and maintenance of heating, ventilation, and air-conditioning (HVAC) systems.
•  The GSA Rent-Related Services include recurring reimbursable services provided by GSA that are over and above the standard eleven hours that GSA covers in its rent charges.  Services include security systems, guard services, and HVAC beyond the standard level funded by GSA.
• The GSA Building Delegation Services account provides recurring services and one-time repairs to operate and maintain buildings delegated to FDA by GSA for management of day-to-day operations. Services include utilities and all recurring services for building operation, such as janitorial, guard, grounds maintenance, and operation and maintenance of HVAC systems.
• FDA will incur costs associated with CFSAN's move to a newly constructed facility in College Park, Maryland.

Buildings and Facilities

^1/ Reflects enacted levels adjusted for the 0.22 percent rescission, accounting for $69,000 in the Building and Facilities program.

Historical Funding and FTE Levels

MISSION

FDA Buildings and Facilities (B&F) appropriation provides funding for needed repairs and improvements to existing owned or leased facilities nationwide.  In addition, as specifically provided, the B&F appropriation funds construction of new FDA special-purpose laboratory facilities.

REQUESTED INCREASES

Complete Construction of the New Los Angeles Field Laboratory + $3,000,000

FDA’s field laboratories provide critical laboratory and analytical support to the domestic and import inspection effort and are a key element in the science base of FDA.  The existing Los Angeles laboratory is an outmoded facility in a high crime area.  The Los Angeles District is responsible for entry decisions on nearly 1.6 million import line entries, almost 25 percent of the Agency total.  In FY 2000 alone, the Los Angeles laboratory analyzed 24.2 percent of the imported foods samples analyzed by FDA.  The capability to test imported products in southern California is a critical need, since FDA does not have the advantage of direct observation of the growing or manufacture of imported products in other countries.

• In FY 2002, FDA requests an additional $3,000,000 for a total of $23,000,000, to continue construction of the Los Angeles replacement laboratory and office space project. Phase II completes the mechanical and electrical infrastructure and completely fits-out both the laboratory and the office at an estimated cost of $23,000,000. Total construction costs are currently estimated at $43,000,000.  Updates to construction costs may be revised as necessary to reflect cost increases in equipment, construction delays, and other possible factors. 

JUSTIFICATION OF BASE

Construction of FDA Los Angeles, California, Replacement Laboratory (Irvine)

In FY 2001, the Agency received $20,000,000 for the first phase of construction, for the core and shell of the project. The $20,000,000 recurs in FY 2002 to fund the majority of the $23,000,000 required to complete the project.

• The replacement laboratory is projected as a 75,000 gross square feet (gsf)/45,000 net square feet (nsf) state-of-the-art laboratory facility housing 75 scientific staff.  The office portion of the new facility is projected at 44,200 gsf/28,000 nsf to house a staff of 120.
• On May 22, 2000, the solicitation for proposals for the construction were made available.   Proposals were received on August 24, 2000, and procurement was completed.   FDA awarded a contract to Hensel Phelps Construction Company on February 27, 2001.  A groundbreaking ceremony was held on March 6, 2001.

Repairs and Improvements

Base resources of $8,281,000 covers the costs of repairs and improvements to FDA facilities, owned and leased.   Included are Washington area headquarters components which are now located in some 40 buildings in eighteen separate locations; plus five regional offices, 19 field District complexes including 19 administrative and 13 specialized laboratory facilities nationwide; more than 120 field resident posts, eight field criminal investigation offices, two distinct program laboratory complexes outside the Washington Metro area; and the NCTR complex in Jefferson, Arkansas.  With all of these Field facilities combined, FDA maintains offices and staff in 49 of the 50 States, and in the District of Columbia and Puerto Rico.

While industry components that FDA regulates spend between nine percent and 12 percent of the value of their physical plants on maintenance, alteration, and repair, FDA has been spending about two percent of the value of its physical plant (laboratories and laboratory support facilities only) for the same purpose.

The following table lists the planned repairs and improvements projects for the FY 2002 request of $8,281,000:

Continued Construction of Arkansas Regional Laboratory (ARL)

• A building dedication ceremony for Phases I & II, the laboratory portion, was held on February 17, 2000; ORA began occupying the laboratory facility in June 2000.

Building 50 Renovation and Common Area status:

• Phase III provides the renovation of the existing Building 50 in its entirety and completes the common ORA/NCTR administrative and support area.
• The FY 1999 appropriation included $3,000,000 to begin construction of a portion of Phase III.   On January 26, 1999, the contractor was given notice to proceed on the first portion of Phase III.
• The FY 2000 appropriation included another $3,000,000 to continue the construction of a portion of Phase III.
• The FY 2001 appropriation included $3,000,000 to continue work on Phase III. The $3,000,000 will be utilized to fund site work between the lab building and Building 50, and restore the NCTR/ORA common area. 
• The $3,000,000 in FY 2002 will be used to continue purchase of Building 50 major mechanical electrical equipment and start the fit out of the building interior.

FDA Home Page | Search | A-Z Index | Site Map | Contact FDA

OC/OFM
Web page edited by sml 06/06/01